Benzinga | May 6, 2021 12:06PM EDT

Canaccord Genuity Maintains Hold on Global Blood Therapeutics, Lowers Price Target to $40

Canaccord Genuity maintains Global Blood Therapeutics (NASDAQ:GBT) with a Hold and lowers the price target from $45 to $40.